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Introduction: Recombinant human erythropoietin (EPO) is known to provide organ protection against
ischemia-reperfusion injury through its pleiotropic properties. The aim of this single-site, randomized, case-controlled,
and double-blind study was to investigate the effect of pre-emptive EPO administration on the incidence of postoperative
acute kidney injury (AKI) in patients with risk factors for AKI undergoing complex valvular heart surgery.
Methods: We studied ninety-eight patients with preoperative risk factors for AKI. The patients were randomly
allocated to either the EPO group (n = 49) or the control group (n = 49). The EPO group received 300 IU/kg of EPO
intravenously after anesthetic induction. The control group received an equivalent volume of normal saline. AKI
was defined as an increase in serum creatinine >0.3 mg/dl or >50% from baseline. Biomarkers of renal injury were
serially measured until five days postoperatively.
Results: Patient characteristics and operative data, including the duration of cardiopulmonary bypass, were similar
between the two groups. Incidence of postoperative AKI (32.7% versus 34.7%, P = 0.831) and biomarkers of renal
injury including cystatin C and neutrophil gelatinase-associated lipocalin showed no significant differences
between the groups. The postoperative increase in interleukin-6 and myeloperoxidase was similar between the groups.
None of the patients developed adverse complications related to EPO administration, including thromboembolic
events, throughout the study period.
Conclusions: Intravenous administration of 300 IU/kg of EPO did not provide renal protection in patients who are at
increased risk of developing AKI after undergoing complex valvular heart surgery.
Trial registration: Clinical Trial.gov, NCT01758861Introduction
Despite advances in the understanding of its pathophysi-
ology, acute kidney injury (AKI) continues to be a serious
complication following cardiac surgery [1]. AKI is an inde-
pendent predictor of both in-hospital and long-term mor-
tality in cardiac surgical patients [2]. Of note, even a minor
increase in serum creatinine (sCr) level is associated with
increased risk of morbidity and mortality, not to mention* Correspondence: ylkwak@yuhs.ac
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reproduction in any medium, provided the orthat the most severe disease spectrum of AKI requires
dialysis [3,4].
Patient-related factors and cardiopulmonary bypass
(CPB) are considered major risk factors for AKI [5]. CPB
is associated with inevitable alterations contributing to
the development of AKI, such as ischemia-reperfusion
injury, systemic inflammatory response, hemodilution,
and embolism [6]. Indeed, the reported incidence of AKI
after cardiac surgeries that required prolonged durations
of CPB reaches 40% to 50%, depending on the chosen
definition [7]. Considering its high prevalence and clear
association with poor prognosis, the development of renal
protective strategies is important, especially in patients. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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requiring prolonged durations of CPB.
Erythropoietin (EPO) is a natural hormone produced
mainly in the kidney that regulates hematopoiesis. Apart
from its hematopoietic effect, recent literature supports
a protective role against ischemia-reperfusion injury through
its anti-oxidative, anti-inflammatory and anti-apoptotic
effects [8-10]. Indeed, EPO has been shown to decrease
myocardial and renal damage after hypoxic insult in nu-
merous experimental studies; however, conflicting results
have been reported in clinical studies [11-13]. Despite its
extensive experimental background, evidence is lacking
regarding EPO’s renal protective effect in cardiac surgical
patients who are at increased risk of developing AKI.
The aim of this single-site, randomized, controlled and
double-blind study is to validate whether a pre-emptive
single bolus of recombinant human EPO mitigates the
occurrence of AKI following complex valvular heart sur-
gery in patients with preoperative risk factors for AKI.
Materials and methods
Patients
After approval by the institutional review board of the
Severance Hospital, Yonsei University Health System,
Seoul, Korea, and procurement of informed consent, we
studied ninety-eight patients with preoperative risk fac-
tors for AKI who were scheduled for complex valvular
heart operations. This single-site trial was conducted at
Yonsei University Health System, Seoul, Korea (Clinical-
Trials.gov NCT0178861). Enrollment criteria for high
risk of AKI included more than two of the following: fe-
male, chronic obstructive pulmonary disease, preoperative
creatinine >1.2 mg/dl, New York Heart Association func-
tional class IV, left ventricle ejection fraction <35%, diabetes
mellitus (DM), age >65 years or peripheral vascular disease
[5]. Complex valvular heart operations were defined as
double-valve surgery, combined valve and coronary artery
bypass grafting procedures, Bentall operations, combined
mitral valve surgery and tricuspid annuloplasty or repeat
operations. Patients with pre-existing uncontrolled hyper-
tension (diastolic blood pressure >100 mmHg), immuno-
suppression, history of thromboembolism, malignant
disease, seizure, liver dysfunction, end-stage renal disease
requiring renal replacement therapy and drug or alcohol
abuse were excluded.
Treatment
Patients were randomly allocated to either the EPO or con-
trol group in a 1:1 ratio according to simple randomization
using a computer-generated random code. Patients in
the EPO group received 300 IU/kg of human recombinant
EPO-alpha (Epocain; CJ Pharma, Seoul, Korea) intraven-
ously after anesthetic induction. Patients in the control
group received an equal volume of normal salineat the same time point. Medications were prepared by a
nurse who knew the patient’s group assignment but was
not involved in the study.
Clinical evaluations
The primary endpoint of interest was incidence of AKI,
which was diagnosed according to the Acute Kidney In-
jury Network (AKIN) criteria (absolute increase in the
sCr concentration ≥0.3 mg/dL from baseline or ≥50%
increase in the sCr concentration within 48 hours after
operation) [14].
The secondary outcomes assessed in this study were
biomarkers of renal injury including sCr, cystatin C, and
estimated glomerular filtration rate (eGFR) which were
recorded 24 hours before operation, upon arrival at the
ICU, and on postoperative days (POD) 1, 2, 3, and 5.
Additionally, changes in serum IL-6, myeloperoxidase
(MPO) and neutrophil gelatinase-associated lipocalin
(NGAL) levels in 18 randomly selected patients from
each group were measured after anesthetic induction, at
1 and 6 hours after removal of the aortic cross clamp
(ACC), and 24 hours after operation. Quantikine® human
IL-6 and Quantikine® human MPO (R&D System Inc.,
Minneapolis, MN, USA) were used to measure IL-6 and
MPO. NGAL was measured by Human Lipocalin-2/
NGAL Immunoassay (R&D System Inc., Minneapolis,
MN, USA).
Preoperative variables included demographic data, type
of operation and co-morbid conditions such as DM, hyper-
tension, chronic kidney disease, cerebrovascular accidents,
congestive heart failure, medications and EuroSCORE.
Intraoperative variables included operation time, dur-
ation of ACC and CPB, fluid balance, and packed erythro-
cyte transfusion requirement. The amount of ultrafiltration
during CPB and the amount of salvaged blood by a cell
salvage device during the operation were also recorded.
Postoperative variables included packed erythrocyte
transfusion requirement, fluid balance and bleeding mea-
sured by chest tube drainage during the 24 hours after the
operation. Hematocrit was measured preoperatively and
on POD 0, 1, 2, 3, and 5. Other postoperative variables
were length of ICU and hospital stay, prolonged mechanical
ventilator care (>48 hours), inotrope use, re-intubation, re-
operation, atrial fibrillation, stroke and in-hospital mortal-
ity. Possible complications associated with EPO treatment,
such as hypertension, headache, tachycardia, nausea, vomit-
ing, diarrhea and thromboembolism, were also assessed
during the study period.
Perioperative management
All patients received standard anesthetic care. Standard
monitoring devices included a pulmonary artery catheter
and transesophageal echocardiography. Mechanical ven-
tilation was controlled to maintain normocarbia with
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14 breaths/minute.
All patients received standard surgical and CPB man-
agement with ultrafiltration. CPB was instituted with a
membrane oxygenator primed with 1.6 L of priming so-
lution. Non-pulsatile pump flow was maintained at a
rate of 2.0 to 2.4 L/min/m2. During the intraoperative
period, including CPB, mean arterial pressure was main-
tained at 50 to 80 mmHg with norepinephrine or sodium
nitroprusside.
During the perioperative period, fluid balance was main-
tained using Voluven® (Fresenius Kabi, Graz, Austria) and
Plasma solution A 1000 inj® (CJ Pharma, Seoul, Korea) to
maintain normovolemic status. Total volume of intraoper-
ative Voluven® was limited to less than 20 ml/kg and/or
1,000 ml. The threshold for transfusion of packed erythro-
cytes was hematocrit <20% during CPB or <25% after
CPB. After heparin was antagonized with protamine,
blood from the CPB circuit was salvaged using a cell sal-
vage device and re-transfused into all patients.
For postoperative hemodynamic management, norepin-
ephrine or nicardipine was used to maintain mean arterial
pressure between 65 to 90 mmHg. As an inotrope, milri-
none was used if the left ventricular ejection fraction was
lower than 30% or in cases of right ventricular dysfunction
and/or pulmonary hypertension. Diuretics were used when
hourly urine output was less than 0.5 ml/kg. Blood glucose
levels were targeted between 100 and 250 mg/dL with
insulin throughout the study period.
Statistical analysis
Data were analyzed with SPSS version 19.0 statistical soft-
ware (SPSS INC, an IBM Company, Chicago, IL, USA)
and SAS version 9.2 (SAS Institute Inc., Cary, NC, USA).
Results are expressed as mean ± SD, median (interquartile
ranges (25th to 75th)) or number of patients (percent-
ages). Continuous variables were compared using inde-
pendent Student’s t-test or Mann–Whitney U test, and
dichotomous variables were compared using chi-square or
Fisher’s exact test as appropriate. The Shapiro-Wilk test
for normality was performed. NGAL and inflammatory
cytokine levels were log-transformed. Repeatedly mea-
sured variables, such as creatinine, cystatin C, eGFR, log
NGAL, log IL-6 and log MPO were analyzed using a lin-
ear mixed model as a group, time and group-by-time as
fixed effects. Type I error was corrected by the Bonferroni
method. All statistical tests were two-tailed. P-value less
than 0.05 was considered statistically significant. In a pre-
vious institutional study, the incidence of AKI following
valvular heart surgery in anemic patients was 54%, [13]
and EPO reduced the incidence of AKI more than 50% in
two previous clinical studies [11,13]. Therefore, we deter-
mined that 49 patients were required in each group to de-
tect a 50% reduction in the incidence of AKI between thegroups to obtain a power of 80%, considering a type I
error of 0.05. Regarding the measurement of NGAL, we
determined that 18 patients were required in each group
to detect a mean difference of 50 ng/ml (SD of 50 ng/ml)
to obtain a power of 80%, considering a type I error of
0.05 [15,16].
Results
A total of ninety-eight patients were randomized to receive
EPO (n = 49) or normal saline (n = 49), and no patient was
dropped out after group allocation (Figure 1). Patients’
characteristics, including demographic data, EuroSCORE
and preoperative renal function were not statistically dif-
ferent between the two groups (Table 1).
Operative characteristics, including the type of surgery
performed, operation time, duration of CPB and ACC
were similar between the two groups. Fluid balance, trans-
fusion requirement, amount of ultrafiltration, re-infused
volume from the cell savage device, vasopressor and ino-
tropic requirement, and postoperative blood loss as mea-
sured by the volume of chest tube drainage were also
similar between the two groups throughout the study
period (Tables 2 and 3).
Overall, AKI occurred in 33 of 98 patients (34%). The in-
cidence of AKI was similar between the groups. Among
the patients who developed AKI, a similar number of pa-
tients required renal replacement therapy during the hos-
pital stay. There were no statistically significant differences
in sCr levels, eGFR, creatinine clearance, cystatin C levels
or serum NGAL levels between the two groups. The
highest sCr level was observed at POD 1 in both groups
(Table 4).
IL-6 and MPO were statistically significantly increased
from their corresponding baseline values after the oper-
ation in both groups without any intergroup differences
(Figure 2).
Perioperative hemodynamic variables, including mean
arterial pressure, heart rate, central venous pressure, pul-
monary capillary wedge pressure and cardiac index, were
not different between the two groups (data not shown).
Pre- and postoperative hematocrit levels were also simi-
lar between the two groups (Table 5).
The lengths of ICU and hospital stays were similar be-
tween the two groups. Remaining postoperative outcome
variables were not different between the groups. One pa-
tient in the control group died during the hospital stay due
to sepsis and acute respiratory distress syndrome (Table 6).
None of the patients developed adverse complications
related to EPO administration including thromboembolic
events throughout the study period.
Discussion
In this randomized controlled trial, we did not observe any
beneficial influence of pre-emptive EPO administration on
Figure 1 Diagram representing study cohort allocation.
Kim et al. Critical Care 2013, 17:R254 Page 4 of 9
http://ccforum.com/content/17/5/R254the incidence of AKI and the degree of renal injury follow-
ing complex valvular heart surgery in patients at risk of
AKI. In addition, EPO did not attenuate the postoperative
increase in IL-6 and MPO levels.
AKI occurs in up to 50% of patients after cardiac opera-
tions depending on the chosen AKI definition or type of
operation [1,17]. AKI is associated with increased resource
utilization and poor prognosis [2]. Known predisposing
risk factors for AKI include advanced age, congestive heart
failure, anemia, diabetes mellitus and decreased basal renal
function [1]. Yet, the predominant risk factor for AKI con-
tinues to be the use of CPB [5,6]. In the pathogenesis of
postoperative AKI, renal ischemia-reperfusion injury and
systemic inflammatory response likely play pivotal roles
[1]. Owing to its unique circulatory characteristics, the
renal medulla is especially vulnerable to ischemic insults,
as it normally receives blood with low oxygen tension
[18]. Thus, the inevitable alterations caused by CPB, such
as hemodilution, renal vasoconstriction, embolism and
systemic inflammatory response, may contribute to the
development of AKI [6]. Indeed, patients undergoing
valvular heart surgery requiring prolonged CPB were
shown to be more vulnerable to AKI [19]. Despite con-
tinuing clinical efforts to diminish renal injury through ab-
rogation of the pathways related to ischemia-reperfusion
injury and inflammation, no intervention has conclusively
proven efficacy.
EPO, an endogenous hormone mainly produced in
interstitial fibroblasts of the renal cortex and outer medulla,
is responsible for stimulating red blood cell development inresponse to hypoxia. In addition, EPO has pleiotropic organ
protection properties and elicits cytoprotective responses in
numerous tissues [9]. In recent years, mounting experi-
mental evidence regarding the cardio-, renal- and neuro-
protective effects of EPO against ischemia-reperfusion or
inflammation-induced injury has been documented [20].
EPO may attenuate apoptosis by reducing oxidative stress
and proinflammatory activation [8]. Despite its sound
experimental background [8,9], only a few human stud-
ies have been performed regarding EPO’s renal protect-
ive effects and these studies have produced conflicting
results [11-13,21].
In a pilot study performed in low-risk patients under-
going coronary artery bypass graft surgery (CABG),
300 IU/kg of EPO significantly decreased the incidence
of AKI and the degree of sCr elevation [11]. The authors
observed similar results in a previous study addressing
the role of 500 IU/kg of preemptive EPO treatment as a
blood conservation strategy in patients undergoing valvu-
lar heart surgery [13]. Since the patients who received
EPO treatment received significantly less transfusion blood,
the renal protective effect of EPO could not be clarified
in that previous study. Clinical evidence regarding the
role of EPO in the prevention of AKI in cardiac surgical
patients who are at increased risk of developing postop-
erative AKI is lacking.
Contrary to our expectations, a pre-emptive single
bolus of 300 IU/kg of EPO neither reduced the incidence
of AKI nor attenuated the increase in biomarkers of renal
injury in this study. Although sCr is widely used for
Table 1 Patients’ demographics and preoperative clinical
data
Variable Control
(number = 49)
EPO
(number = 49)
P value
Age (years) 62 ± 10 63 ± 10 0.880
Female 24 (49) 20 (41) 0.417
BMI (kg/m2) 24 ± 4 24 ± 3 0.528
Operation
MVR + TAP 6 (12) 8 (16) 0.564
Multi valve 22 (45) 20 (41) 0.683
Valve + CABG 8 (16) 7 (14) 0.779
Bentall 13 (27) 14 (29) 0.821
Redo 6 (12) 4 (8) 0.505
NYHA
I-II 42 (86) 43 (88) 0.766
III-IV 7 (14) 6 (12)
EuroSCORE 5.1 ± 2.6 5.7 ± 2.5 0.299
DM 8 (16) 16 (33) 0.060
Hypertension 24 (49) 27 (55) 0.544
Chronic kidney disease 14 (29) 10 (20) 0.347
Chronic obstructive lung
disease
2 (4) 0 (0) 0.495
Ejection fraction (%) 60 ± 13 60 ± 12 0.798
Preoperative eGFR 77 ± 30 83 ± 28 0.378
Preoperative
CrCl <60 ml/min
21 (43) 17 (35) 0.407
Medication
β-blockers 18 (38) 14 (29) 0.350
CCB 17 (35) 13 (27) 0.344
ACEi 17 (35) 12 (25) 0.240
ARB 16 (33) 13 (27) 0.464
Diuretics 28 (58) 28 (57) 0.906
Preoperative hematocrit (%) 38 ± 6 39 ± 4 0.375
Values are mean ± SD or number of patients (%). ACEi, angiotensin-converting-
enzyme inhibitors; ARB, angiotensin II receptor blockers; BMI, body mass index;
CCB, calcium channel blockers; CrCl, creatinine clearance; DM, diabetes melli-
tus; eGFR, estimated glomerular filtration rate; EPO, erythropoietin; Multi valve,
more than two valve replacement; MVR, mitral valve replacement; NYHA, New
York Heart Association Functional Classification; TAP, tricuspid annuloplasty;
Valve + CABG, valvular replacement with coronary artery bypass grafting.
Table 2 Intraoperative parameters and fluid balance
Variable Control
(number = 49)
EPO
(number = 49)
P value
Operation time (min) 253 ± 68 243 ± 63 0.480
CPB time (min) 129 ± 42 128 ± 39 0.870
ACC time (min) 96 ± 38 96 ± 30 0.894
Norepinephrine
infused (μg)
70 (40 to 117) 68 (36 to 101) 0.350
Amount of
ultrafiltration (ml)
1,000 (563 to 1,575) 1,000 (450 to 2,000) 0.936
Fluid balance during
operation
crystalloid (ml) 1,570 ± 531 1,579 ± 487 0.934
colloid (ml) 500 (350 to 600) 450 (300 to 575) 0.398
urine output (ml) 1,022 ± 493 1,004 ± 505 0.863
Amount of pRBC
transfusion (ml)
219 ± 384 122 ± 162 0.107
Amount of cell
salvaged blood (ml)
550 (490 to 765) 500 (480 to 748) 0.268
Patients transfused
with pRBCs (number)
20 (41) 21 (43) 0.838
Values are mean ± SD or median (25th to 75th). ACC, aorta cross clamp; CPB,
cardiopulmonary bypass; EPO, erythropoietin; pRBCs, packed red blood cells.
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late indicator of renal dysfunction and an inaccurate de-
tector of mild renal impairment [22]. Cystatin C is more
precise in detecting early and mild renal impairment than
sCr [23]. Likewise, NGAL discriminates patients with sub-
clinical AKI accompanied by normal sCr [24] and is an ef-
fective predictor of AKI after CABG [25]. As we could not
observe any differences in the levels of cystatin C or
NGAL between the two groups in the current trial, EPOdoes not seem to provide any renal protection to the pa-
tient population in this study. Furthermore, the given dose
of EPO did not exert any influence on the IL-6 and MPO
levels in this study. IL-6 is a reliable marker of inflamma-
tory cascade activation and is an indicator of poor out-
comes [26], whereas MPO represents polymorphonuclear
leukocyte accumulation [27]. Leukocyte infiltration is one
of the key initiating processes of renal ischemia-reperfusion
injury [28]. Both IL-6 and MPO were significantly attenu-
ated with EPO in an experimental ischemic myocardial
model [10,27] but not in this study.
There are several plausible explanations for the lack of
benefit from EPO treatment. First, as our results indi-
cate, the percentage of patients requiring renal replace-
ment therapy was higher in the current trial compared
with other studies [11,12]. Thus, the employment of a
single preventive strategy to mitigate the development of
AKI may not be enough to inhibit the numerous intercon-
nections of signaling pathways that lead to renal injury.
Multimodal strategies acting on various mechanisms may
be required to mitigate the incidence of AKI in this high-
risk group of patients. Second, the optimal dosage of EPO
treatment to induce tissue protection has not been estab-
lished clinically. In the present study, the dose of EPO
(300 IU/kg) was decided based on a previous clinical study
demonstrating the renal protective effects of EPO in low-
risk patients undergoing CABG [11]. Although most of
the patients in that study underwent off-pump CABG,
CPB was reported to have no apparent influence on the
pharmacokinetics of a single bolus of EPO [29]. The
Table 3 Postoperative care at ICU
Variable Control
(number = 49)
EPO
(number = 49)
P value
Crystalloid infused (ml)
at ICU POD 0 2795 ± 994 3045 ± 1054 0.231
at ICU POD 1 2380 ± 695 2261 ± 861 0.452
Colloid infused (ml)
at ICU POD 0 280 (100 to 500) 150 (0 to 500) 0.139
at ICU POD 1 0 (0 to 0) 0 (0 to 0) 0.317
Urine output (ml)
at ICU POD 0 2,180 ± 701 2,389 ± 832 0.182
at ICU POD 1 2,520 ± 722 2,628 ± 537 0.401
pRBCs transfused (ml)
at ICU POD 0 223 ± 344 222 ± 601 0.987
at ICU POD 1 63 ± 182 44 ± 136 0.555
Chest tube drainage (ml)
at ICU POD 0 390 (195 to 580) 330 (195 to 595) 0.394
at ICU POD 1 240 (165 to 375) 270 (180 to 440) 0.153
Patients transfused
with pRBCs (number)
at POD 0 and 1
16 (33) 23 (47) 0.149
Patients treated with
vasopressors (number)
at POD 0 and 1
18 (37) 12 (25) 0.188
Patients treated with
inotropics (number)
at POD 0 and 1
21 (43) 17 (35) 0.407
Values are mean ± SD or median (25th to 75th). ACC, aorta cross clamp; CPB,
cardiopulmonary bypass; EPO, erythropoietin; POD, postoperative day; pRBCs,
packed red blood cells.
Table 4 Variables associated with renal outcomes
Variable Control
(number = 49)
EPO
(number = 49)
P
value
Postoperative AKI 16 (0.33,
0.26 to 0.39)
17 (0.35,
0.28 to 0.42)
0.831
Stage 1 12 (0.25,
0.18 to 0.31)
12 (0.25,
0.18 to 0.31)
1.000
Stage 2 0 0 1.000
Stage 3 4 (0.08,
0.04 to 0.12)
5 (0.10,
0.06 to 0.15)
0.727
Postoperative
dialysis
4 (0.08,
0.04 to 0.12)
5 (0.10, 0.06 to
0.15)
0.727
Serum creatinine
(mg/dl)
0.090b
Baseline 0.99 ± 0.27 0.92 ± 0.28 0.218
ICU arrival 0.89 ± 0.25a 0.92 ± 0.34 0.546
POD 1 1.13 ± 0.39a 1.08 ± 0.46a 0.588
POD 2 1.09 ± 0.55 1.07 ± 0.50a 0.795
POD 3 1.00 ± 0.54 0.96 ± 0.52 0.754
POD 5 0.87 ± 0.35a 0.85 ± 0.52 0.934
Cystatin C (mg/L) 0.423b
Baseline 1.13 ± 0.37 1.04 ± 0.28 0.191
ICU arrival 1.00 ± 0.27a 0.95 ± 0.31 0.457
POD 1 1.08 ± 0.36 1.09 ± 0.39 0.912
POD 2 1.30 ± 0.54a 1.26 ± 0.57a 0.736
POD 3 1.58 ± 0.89a 1.54 ± 0.88a 0.898
eGFR
(mL/min/1.73 m2)
0.759b
Baseline 77 ± 30 83 ± 28 0.381
ICU arrival 89 ± 36a 94 ± 46a 0.556
POD 1 80 ± 46 79 ± 43 0.941
POD 2 72 ± 36 71 ± 30a 0.985
POD 3 79 ± 35 76 ± 30 0.659
POD 5 88 ± 32a 89 ± 30a 0.863
Log NGAL 0.891b
Baseline 1.53 ± 0.28 1.56 ± 0.26 0.780
1 hourr
after ACC off
2.21 ± 0.26a 2.16 ± 0.28a 0.591
6 hourr after
ACC off
2.24 ± 0.33a 2.17 ± 0.33a 0.550
24 hourr after
operation
2.17 ± 0.37a 2.14 ± 0.36a 0.846
Values are number of patients (probability, 95% confidence interval) or mean ± SD.
aP <0.05, compared with baseline; bPgroup x time = P-value of the group and time
interaction obtained by the linear mixed model. ACC, aortic cross clamp; AKI,
acute kidney injury; eGFR, estimated glomerular filtration rate; EPO, erythropoietin;
Log NGAL, logarithm of neutrophil gelatinase-associated lipocalin;
POD, postoperative days.
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ous study might be associated with the different degree of
the risk of the enrolled patients for postoperative AKI and
the degree of inflammatory and oxidative stress between
both studies.
Generally, higher doses of EPO are considered neces-
sary for tissue protection than for erythropoiesis because
of the lower affinity of the EPO heteroreceptor [9,30].
On the other hand, EPO’s organ protective effects at
lower dosages (<500 IU/kg) have also been observed [31].
Similarly, some studies using higher doses of EPO have
failed to show a beneficial effect [32]. Indeed, no differ-
ence in changes of urinary NGAL has been reported in
a study that randomized post cardiac surgical patients
up to 40,000 IU EPO, which is in accordance with the
results of the current study [12]. Although used in a dif-
ferent clinical setting, doses up to 60,000 IU used in pa-
tients with myocardial infarction within four-hour
reperfusion also could not provide any beneficial influ-
ence in terms of infarct size reduction [33]. Of note, the
incidence of adverse cardiovascular events including
death was significantly higher in patients who receivedEPO in that study, raising alarm against the use of higher
doses of EPO.
Despite the organ protective effects observed in animal
experiments, a recently increasing amount of negative
Figure 2 Changes of log transformed serum interlukin-6 (A)
and myeloperoxidase (B) over time in the control group and
EPO group. Values are mean ± SD. EPO, erythropoietin; Log IL6,
logarithm of interlukin 6; Log MPO, logarithm of myeloperoxidase.
*P <0.05, compared with baseline (type I error was corrected by
Bonferroni method, all time points were statistically significantly
different from baseline).
Table 6 Postoperative outcome
Variable Control
(number = 49)
EPO
(number = 49)
P value
Duration of ICU stay (days) 4.0 ± 5.1 3.5 ± 2.8 0.593
Duration of hospital stay
(days)
14 (12 to 18) 15 (12 to 18) 0.695
Ventilatory care >48 hours 3 (6) 2 (4) 0.646
Postoperative inotrope use 17 (35) 13 (27) 0.381
Re-intubation 0 (0) 2 (4) 0.495
Re-operation 2 (4) 3 (6) 1.000
Postoperative atrial
fibrillation
14 (29) 9 (18) 0.233
Stroke 1 (2) 2 (4) 1.000
Death 1 (2) 0 (0) 1.000
Values are mean ± SD or median (25th to 75th) or number of patients (%).
EPO, erythropoietin.
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has been documented in clinical trials. In terms of EPO’s
anti-inflammatory effects, EPO did not suppress the sys-
temic inflammatory response [12,26] and, instead, aug-
mented the cytokine response to acute inflammation
[34]. In accordance with those reports, no convincing
trend in any of the serum levels of MPO and IL-6 was
observed in the EPO group in the current trial. Of inter-
est, one experiment in a porcine model suggested that
EPO may protect against injuries related to direct ische-
mia but not injuries related to inflammation [32]. Con-
sidering that most experimental studies reporting the
renal protective effects of EPO used a direct renal
ischemia-reperfusion model, different mechanisms and
degrees of renal injury in procedures using CPB without
overt mechanical renal ischemia could also be responsibleTable 5 Changes of hematocrit during perioperative
period
Group Preoperative POD 0 POD 1 POD 2 POD 3 POD 5
Control
(n = 49)
38 ± 6 31 ± 4 29 ± 3 28 ± 3 27 ± 3 27 ± 3
EPO
(n = 49)
39 ± 4 31 ± 5 29 ± 4 28 ± 4 28 ± 4 29 ± 3
P value 0.375 0.756 0.227 0.369 0.192 0.131
Values are mean ± SD. EPO, erythropoietin; POD, postoperative days.for the different results observed in clinical trials. As yet,
the promising organ protective effects of EPO in experi-
mental studies could not be consistently reproduced in
clinical trials for numerous possible reasons that are be-
yond the scope of this study.
There are several limitations of this study. First, the
sample size may not have been sufficient, as the actual
incidence of AKI was lower than expected. Still, we did
not observe any trend indicating a potential benefit of
EPO, even with the sensitive biomarkers of renal injury
known to detect subtle forms of renal dysfunction. There-
fore, it seems reasonable to conclude that the given dose
of EPO does not offer renal protection in the studied
population. Second, more patients had DM in the EPO
group, although these results were not statistically signifi-
cant. DM was reported to mitigate the tissue protective ef-
fect of EPO, as well as various preconditioning strategies
in animal studies [35-39]. There were no differences in
mean blood glucose levels, renal biomarkers and the inci-
dence of AKI between the groups even in patients without
DM (data not shown). Moreover, DM as covariate in the
linear mixed model for sCr to test whether it changes by
the group and time interaction did not show any inter-
group difference (P = 0.935); thus, the confounding effect
of DM should be negligible. Third, the use of Voluven®
might have confounded the results. Increasing evidence
warns about the potentially harmful influence of hydro-
xyethyl starch solutions on AKI in critically ill patients
[16,40]. However, the use of a limited amount of low mo-
lecular weight hydroxyethyl starch (less than 500 ml of
Voluven® per day) does not seem to exert any influence on
AKI as evidenced by the lack of association between the
amount of Voluven® and changes in sCr in the current
study (data not shown). Also, as both groups received a
similar amount of Voluven® during the study period, its in-
fluence should be the same, if any should exist.
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Intravenous administration of a pre-emptive single bolus
of 300 IU/kg of EPO did not decrease the incidence of
AKI. It also failed to attenuate the increase in the serum
levels of biomarkers of renal injury and Il-6 and MPO
activation. A single preventive strategy, such as EPO,
may not suffice in patients at increased risk of developing
AKI after undergoing complex valvular heart surgery.
Key massages
 Intravenous administration of a pre-emptive single
bolus of 300 IU/kg of EPO did not decrease the
incidence of acute kidney injury.
 It also failed to attenuate the increase in the serum
levels of biomarkers of renal injury, such as sCr,
cystatin C and NGAL.
 In terms of the anti-inflammatory effects of EPO,
administration of a preemptive single bolus of
300 IU/kg of erythropoietin did not decrease IL-6
and MPO.
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